California: Apple has opted to eliminate the blood oxygen measurement feature from two of its watch models in an effort to prevent a potential sales ban in the United States, as reported by Bloomberg. This decision follows a prior suspension of Apple Watch sales due to a patent dispute related to the devices’ pulse oximeter capability.
The blood oxygen monitor, a crucial health feature, enables users to assess the oxygen levels in their blood to ensure it remains at a healthy level, preventing potential serious health issues. The International Trade Commission (ITC) determined that Apple had unlawfully incorporated blood oxygen technology developed by Masimo, a medical tech company. Consequently, the affected devices were withdrawn from the market.
Masimo responded to Apple’s move by describing it as “a positive step toward accountability”. A Masimo spokesperson emphasized the significance of a major company like Apple respecting the intellectual property rights of smaller entities and complying with ITC orders when found infringing.
Although a federal court temporarily lifted the sales halt in December 2023, allowing the two watch models, Series 9 and Ultra 2, to return to the market, Apple faced challenges due to the ITC ruling. Apple’s online sales in the US were disrupted before Christmas, but the company confirmed the availability of the two watch models on its online store by December 28. The products became more widely accessible by December 30.
Pulse oximetry, the contested feature, is a medical test that measures the oxygen saturation in the blood. Typically, a probe is placed on body parts like a finger or earlobe, using light to gauge the oxygen levels. The results assist healthcare providers in determining whether a person requires additional oxygen.
